Biosimilars – Current Treatment – Ophthalmology

The ophthalmology market is relatively new in the field of biosimilars: Samsung Bioepis / Biogen’s ranibizumab biosimilar, Byooviz, was the first MAb biosimilar to launch in the U.S. market in 2022, followed by Formycon / Coherus’s biosimilar, Cimerli, in October 2022. Amgen’s aflibercept biosimilar, Pavblu, launched at risk in the United States in October 2024. More biosimilars are expected to launch in 2027 and onwards. In Europe, Formycon / Teva’s ranibizumab biosimilar, Ongavia, became the first biosimilar to enter the U.K. market in July 022, followed by its launch in Germany later that year. Xbrane / STADA launched their ranibizumab biosimilar, Ximluci, in several European countries in April 2023, followed by launch of Samsung Bioepis / Biogen’s Byooviz in Germany in June 2023. Qilu Pharma’s Rimmyrah received EC approval in January 2024 and launched in mid-2025 in Germany, followed by other European countries. To help manufacturers / marketers of ophthalmology biosimilars and brands understand the opinions, actions, and expectations of these physicians, Clarivate has conducted new primary market research with ophthalmologists in France, Germany, and the United States on the use of branded drugs versus their biosimilar competitors.

Questions answered

• What is the current patient share of ophthalmology biosimilars, and what expectations do ophthalmologists have about future patient shares, assuming additional biosimilars launch?
• What factors do ophthalmologists identify as being the key drivers and barriers to biosimilar uptake?
• What percentage of biosimilar-treated patients were initiated on a biosimilar, and what percentage were switched from a reference brand?
• What cost reduction is required for a biosimilar to achieve more than a 50% patient share?

Content highlights

Key markets covered: United States, France, Germany

Key companies mentioned: Amgen, Bayer, Biogen, Genentech, Novartis, Roche, Sandoz, STADA, Teva

Key drugs mentioned: Lucentis, Susvimo, Eylea, Beovu, Vabsymo, Byooviz, Ximluci, Ranivisio / Cimerli

Product description

Current Treatment: Biosimilars in Ophthalmology provides ophthalmologists’ insights on treatment dynamics, prescribing behavior, and drivers of biosimilar use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.